KIT and prostate carcinoma: From pathway enrichment, PF-L metabolites potentially regulate the AMPK signaling pathway, EGFR tyrosine kinase inhibitor resistance, miRNAs in cancer, prostate cancer, steroid and lipid metabolism, SCF-KIT and PIK3/Akt signaling pathways, EPH-ephrin mediated cell repulsion, and the VEGFA-VEGFR2 pathway.